Live
- Ambati, Bhashyam file nominations
- Lemon vendor Mallamma files nomination
- Hyderabad: Sneha Mehra appointed as DCP (South)
- Hyderabad: HMWSSB training programme concludes
- Hyderabad: GHMC summer camps kick off
- All set for Polycet-2024 tomorrow
- Dr Srinivas gets best veterinary surgeon award
- Hyderabad: Jobs top debutant voters’ wish list
- Devotees rush increases at Tirumala today, to take 8 hours for sarva darshans
- Sajjala denounces Naidu’s ‘heinous politics’
Dr Reddy’s gets zero observations for Miyapur center
Shares of Dr Reddy’s Lab closed higher Rs172.85 or 7.47 percent at Rs2,486.45 on BSE. The market valuation of Dr Reddy\'s Lab went up by Rs2,864.35 crore to Rs 41,223.35 crore.
Hyderabad: Global drug major Dr Reddy’s Laboratories Ltd (DRL) on Thursday said that it has received zero observations for its custom pharmaceutical services (CPS) facility, technology development centre (TDC-1) at Miyapur in Hyderabad. US FDA has completed audit of CPS and TDC-1 facilities with zero observations, according to a communique to BSE.
Shares of Dr Reddy’s Lab closed higher Rs172.85 or 7.47 percent at Rs2,486.45 on BSE. The market valuation of Dr Reddy's Lab went up by Rs2,864.35 crore to Rs 41,223.35 crore.
- Receives EIR for its Srikakulam plant; stock soars over 7%; mcap rises by `2,864 cr
On NSE, shares of the company soared 7.42 per cent to close at Rs2,486.55.In a separate filing to BSE, the drug major said that it has also received establishment inspection report (EIR) from the US health regulator for a unit of its Srikakulam plant in Andhra Pradesh.
The company has received EIR from the United States Food and Drug Administration (US FDA) for its formulations manufacturing facility at Srikakulam unit II. However, the company did not state if the US health regulator had made any observation in the EIR.
